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controls. Using a novel competitive Luminex-based assay, 
eight of these proteins [alpha toxin, Staphylococcus aureus 
formyl peptide receptor-like 1 inhibitor (FlipR), glucosa-
minidase, iron-responsive surface determinants A and H, 
the putative ABC transporter SACOL0688, staphylococ-
cal complement inhibitor (SCIN), and serine–aspartate 
repeat-containing protein E (SdrE)] were also detected in a 
majority of the infecting isolates during biofilm formation 
in vitro. However, 4 other proteins were detected in only 
a minority of isolates in vitro while, vice versa, 7 proteins 
were detected in multiple isolates in vitro but not associ-
ated with significantly increased IgG levels in patients. 
Detection of proteins was largely confirmed using a tran-
scriptomic approach. Our data provide further insights 
into potential therapeutic targets, such as for vaccination, 
to reduce S. aureus virulence and biofilm formation. At the 
same time, our data suggest that either in vitro or immuno-
logical in vivo data alone should be interpreted cautiously 
and that combined studies are necessary to identify poten-
tial targets.
Keywords Staphylococcus aureus · Osteomyelitis · 
Biofilm · Virulence factors · Luminex
Introduction
Staphylococcus aureus is the most common causative 
organism of osteomyelitis [1–3], which is defined as an 
infection of the bone and is associated with significant mor-
bidity [1, 4, 5]. Treatment is often difficult and requires sur-
gery in addition to antibiotics [5]. Osteomyelitis is associ-
ated with the formation of bacterial biofilms [3, 6], which 
are defined as complex communities of bacteria enclosed 
in a polymer matrix that differ significantly in their gene 
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expression and protein production compared to free-liv-
ing bacteria [7]. Biofilm formation is believed to increase 
resistance against antibiotics and the host immune system, 
which further complicates the treatment of such infections 
[3, 8, 9].
Together with the increasing incidence of resistant S. 
aureus isolates [10, 11], the difficult treatment of osteomy-
elitis underscores the need for alternative treatment strate-
gies. One such strategy is the development of a vaccine [12]. 
However, so far no clinically successful vaccine against S. 
aureus has been developed, despite the promising results of 
vaccines targeting diverse virulence factors of this pathogen 
in animal models [13–15], including an animal model for 
osteomyelitis [16]. Possibly, so far clinically evaluated vac-
cines might have failed because these were based on single 
antigens, while the awareness is currently increasing that 
multiple virulence factors of S. aureus should be targeted to 
undermine bacterial virulence [12, 13].
Although diverse virulence factors of S. aureus have 
been associated with biofilm formation [17–21], so far only 
a limited number of studies has focussed on the presence of 
multiple virulence factors simultaneously in biofilms [22, 
23]. In addition, most of these studies used in vitro and/or 
animal models, while it remains unclear whether proteins 
expressed in these models are also involved in infection 
in humans. Finally, the immunogenic potential of proteins 
that are specifically expressed during a biofilm-associated 
infection remains unknown, as studies examining the 
immune response against S. aureus in patients have so far 
mainly focused on acute infections, such as bacteremia 
[24–29].
The aims of the present study were to characterize IgG 
responses in 10 patients with chronic osteomyelitis against 
50 proteins of S. aureus, to analyze the presence of these 
proteins in biofilms of S. aureus isolates from the same 
patients on polystyrene (PS) and human bone in vitro, 
and to explore the relation between in vivo and in vitro 
data. All 50 proteins are functionally well-characterized 
virulence factors which have been a major focus of many 
immunoproteomic studies, including vaccination trails, in 
both animal models [13–15] and humans [25, 29–31]. This 
study provides further insights into the presence and immu-
nogenicity of these proteins during a biofilm-associated 
chronic infection in humans.
Materials and methods
Human serum and tissue
All patient serum used in this study was obtained from 
coded leftover material from routine diagnostic blood 
samples as described previously [29]. This procedure was 
approved, and the acquisition of additional written consent 
was waived specifically for this study by the Medical Ethics 
Committee of the Erasmus University Medical Center Rot-
terdam (MEC-2007-106). Human bone was derived from 
surplus tissue obtained during routine orthopedic surgical 
procedures, and all tissue was directly anonymized upon 
arrival at the laboratory. This procedure was approved, and 
the acquisition of additional written consent was waived 
by the Medical Ethics Committee of the Erasmus Univer-
sity Medical Center Rotterdam (MEC-2004-322). None of 
the authors were involved in the direct collection of either 
blood or tissue from patients. Only qualified physicians 
(MdR and MS) had access to potentially identifying patient 
information.
Patients
Ten patients diagnosed with chronic osteomyelitis at the 
Erasmus Medical Center between March 2007 and March 
2011 were included in this study (all male, median age 
62 years, interquartile range (IQR) 49–69 years). Chronic 
osteomyelitis was defined as a history of at least 1 year of 
clinical and radiological signs indicative of osteomyeli-
tis combined with the isolation of S. aureus from at least 
one deep bone culture. Isolates from 9 patients could be 
retrieved for this study. The cause of osteomyelitis varied, 
being iatrogenic following surgery (4 patients), fracture 
or other trauma (3 patients), diabetic ulcer (2 patients), 
or hematologic metastasis from another focus (1 patient). 
Infections were localized in the femur (3 patients), small 
bones of the foot (3 patients), tibia (2 patients), ulna and 
sternum (each 1 patient). Nasal carrier status for S. aureus 
was not tested.
A median number of 4 serum samples were collected 
per patient (IQR 2–5) over a median period of 26 days 
following the most recent positive bone culture (IQR 
9.5–85.5 days). Peak antibody levels of each patient were 
compared with those measured in single serum samples 
of 10 previously described bacteremia patients (80 % 
male, median age 64 years, IQR 45–84) and 20 previously 
described, age-matched controls (all male, median age 
62 years, IQR 57–67) who had no record of a clinically 
apparent infection in at least 6 months [29]. S. aureus nasal 
carrier status was tested neither in patients nor in controls.
Bacterial strains and genotyping
S. aureus isolates obtained from deep bone cultures were 
identified on the basis of colony and microscopic mor-
phology and Slidex Staph Plus agglutination testing (bio-
Mérieux, Marcy l’Etoile, France). Identification was con-
firmed by spa-PCR, and all isolates were spa-typed [32]. 
All isolates were methicillin-sensitive as determined by 
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cefoxitin disk diffusion according to the CLSI criteria [33]. 
Antimicrobial susceptibility to additional antibiotics was 
determined using the VITEK® 2 system with card AST-
P549 (bioMérieux).
Isolates were further typed using pulsed-field gel elec-
trophoresis (PFGE) with Sma1-digested chromosomal 
DNA as described previously [34]. Relatedness among the 
PFGE profiles was evaluated using Bionumerics software 
(version 3.0; Applied Maths, Ghent, Belgium). Finally, all 
isolates were screened with PCR for the presence of 50 
genes using previously described primers [29].
Preparation of human serum and measurement 
of antibodies
Serum samples were collected in BD Vacutainer® SST II 
Advance plastic serum tubes, which were centrifuged 
for 3 min at 1680g and stored at 4 °C. For long-term use, 
serum was aliquoted in 1.5-ml Eppendorf® tubes and stored 
at −80 °C.
IgG levels against 50 recombinant S. aureus proteins 
were measured in serum samples using a bead-based flow 
cytometry technique (xMAP®; Luminex® Corporation, 
Austin, TX, USA), as previously described [29]. Protein 
names are described in Online Resource 1. Proteins were 
coupled to xMAP® carboxylated beads (Luminex Corpora-
tion) as described previously [29, 35]. All measurements 
were taken in duplicate, and the median fluorescence inten-
sities (MFIs), a semiquantitative measure of antibody lev-
els, were averaged. Duplicate measurements for which the 
coefficient of variation was larger than 25 % were excluded 
from further analysis. All measurements were corrected for 
non-specific background signal by subtracting the MFIs of 
control beads not coupled to any protein.
Preparation of human bone
Fresh human bone was obtained in the operating room 
from patients receiving a total hip prosthesis, for purposes 
other than this study, in the Erasmus Medical Center from 
the period of January 2012 until February 2013. All opera-
tions were performed by the same orthopedic surgeon (Dr. 
P.K. Bos). After removing the femoral head, a small portion 
of the surplus tissue was cut using a saw and directly trans-
ported to the laboratory in sterile saline. Spongious bone 
was harvested from the tissue and cut into small pieces fit-
ting in a 96-well plate. The samples were rinsed repeatedly 
with saline until all blood was visibly removed.
Biofilm formation on polystyrene and human bone
A routine biofilm model was used as described before [20, 
36–38]. Briefly, overnight cultures of S. aureus grown on 
sheep blood agar were suspended in Iscove’s Modified 
Dulbecco’s Medium (IMDM, Life technologies, Carls-
bad, CA, USA) without phenol red until an OD660 of 
2.0 was reached. One µl of this bacterial suspension was 
added to 199 µl of IMDM in sterile, 96-well polystyrene 
plates (Greiner Bio-one GmbH, Kremsmuenster, Austria). 
Duplicate wells not inoculated with bacteria served as ster-
ile controls. Plates were then incubated at 37 °C and gen-
tle shaking at 200 rpm for various intervals. Biofilm mass 
was measured by staining with 1 % crystal violet. OD was 
measured at 490 nm.
Alternatively, standard-sized pieces of freshly isolated 
human bone were washed in sterile water and then added 
to 199 µl of IMDM in the same 96-well plates in which 
biofilms on PS were grown. One µl of the same bacterial 
suspension as described above was added before incuba-
tion. Duplicate wells with bone tissue were not inoculated 
to serve as sterile controls.
Multiplex bead assay for assessment of protein levels 
in biofilms
A previously described multiplex competition Luminex® 
assay (CLA) was used to indirectly detect the presence of 
50 IgG-accessible proteins in biofilms [39, 40]. In brief, 
biofilms grown on PS and bone were washed once with ice-
cold PBS supplemented with 0.5 % (wt/v) sodium azide 
(Sigma-Aldrich) at 1, 8, 24, or 48 h to remove non-adherent 
bacteria. Bone tissue with attached biofilms was transferred 
to a clean well. Biofilms were then incubated for 35 min 
at 8 °C and continuous shaking (500 rpm) with 200 µl of 
a 1:200 dilution of polyclonal human IgG (PHG), isolated 
using the HiTrap™ Protein G HP column according to the 
manufacturer’s guidelines (GE Healthcare Bio-sciences, 
Piscataway, New Jersey, USA), from pooled serum of 40 
healthy volunteers [41].
After incubation, the remaining non-bound IgG antibody 
levels in recovered PHG samples were measured using the 
multiplex bead-based flow cytometry technique (xMAP®, 
Luminex corporation), with recombinant proteins cova-
lently coupled to the beads, as described above. As negative 
controls PHG samples incubated with empty PS wells or 
sterile bone pieces were included in all experiments.
Next, the percentage decrease in the levels of specific 
IgG antibodies for each protein was calculated in relation 
to the negative control. The percentage decrease can be 
considered as a semiquantitative measure of the protein-
specific antibody absorption from PHG by the biofilm, thus 
indirectly reflecting the presence of the particular S. aureus 
protein in the biofilm [39, 40]. The average percentage 
decrease plus two times the standard deviation, obtained at 
24- and 48-h biofilm growth, for two non-S. aureus control 
proteins [Streptococcus pneumoniae putative proteinase 
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maturation protein A (PpmA) and human metapneumo-
virus surface protein (hMPV)] and all S. aureus proteins of 
which genes were not present in an isolate were chosen as 
cutoff value (35 % at 24-h biofilm growth and 42 % at 48 h, 
respectively).
Reverse transcriptase PCR
Biofilms were grown on PS for 8 and 24 h in 96-well plates 
in 200 µl of IMDM. Biofilms harvested from 8 wells were 
washed in PBS, resuspended, pooled, and centrifuged at 
4000 rpm for 10 min at 4 °C. Pellets were resuspended 
in 200 µl of RNA protect™ Bacterial reagents (Qiagen), 
stabilized for 5 min, and then centrifuged for 10 min at 
4 °C. The pellet was dissolved in 1 ml of RNA-pro solu-
tion (Fast RNA Pro Blue kit, MP Biomedicals) and stored 
at −20 °C until use. RNA was isolated using the Fast RNA 
Pro Blue kit according to the manufacturer’s protocol. 
Each 10 µg of isolated RNA was treated twice with 2 U 
TURBO DNase (Ambion, Life Technologies). The reaction 
was stopped by adding 0.2 volumes of DNase inactivation 
reagent (Ambion) and incubated for 2 min at ambient tem-
perature. RNA-containing supernatants were collected by 
centrifugation (1.5 min at 9000g at ambient temperature), 
and each 2 µg DNase-treated RNA was treated with 2 U 
DNase I (Fermentas, Fisher Scientific). One µg of prepared 
RNA was transcribed into cDNA using 200 U RevertAid H 
Minus Reverse transcriptase (Fermentas), 4 µl of 5 × reac-
tion buffer (Fermentas), 20 U of RiboLock RNase inhibitor 
(Fermentas), and 2 µl of 10 mM dNTP mix (Fermentas) in 
a final volume of 20 µl of DEPC-treated water. This was 
incubated for 60 min at 42 °C and then terminated by heat-
ing at 70 °C for 5 min. For each RNA sample, a negative 
control without reverse transcriptase was processed simi-
larly. The presence of cDNA in all samples was examined 
using PCR as described previously [29].
Cryo‑scanning electron microscopy
The clinical isolate from one osteomyelitis patient was 
allowed to form biofilms on human bone for 24 h as 
described above. Next, S. aureus in bone was fixed for 
15 min with 1 % (v/v) glutaraldehyde (Sigma) in phos-
phate-buffered saline (PBS) at room temperature. Samples 
were washed twice with PBS to remove excess fixative 
and were subsequently serially dehydrated by consecutive 
incubations in 1 ml of 25 % (v/v) and 50 % (v/v) ethanol–
PBS, 75 % (v/v) and 90 % (v/v) ethanol–H2O, and 100 % 
ethanol (2x), followed by 50 % ethanol–hexamethyldisi-
lazane (HMDS) and 100 % HMDS (Sigma) and air-dried 
overnight at room temperature. After overnight evaporation 
of HMDS, bone samples were mounted on 12-mm speci-
men stubs (12 mm, Agar Scientific) and coated with gold 
to 1 nm using a Quorum Q150R sputter coater at 20 mA 
prior to examination with a Phenom PRO Table-top scan-
ning electron microscope (PhenomWorld).
Statistics
Mean IgG levels between patient groups and controls were 
compared using one-way ANOVA. All data were logarith-
mically transformed to obtain equal variances between 
groups, checked with Levene’s test for equality of vari-
ances. For proteins that were associated with a significant 
difference in the ANOVA, additional least significant dif-
ference (LSD) post hoc tests were performed for further 
group comparisons.
Correlation between biofilm mass and the percentage 
decrease in specific IgG levels, as obtained with CLA, was 
determined by calculating the nonparametric Spearman’s 
rank correlation coefficient (rs).
In all cases, p values ≤ 0.05 were considered as statisti-
cally significant. IBM® SPSS® Statistics version 21 (IBM 
corporation, Armonk, NY, USA) was used for statistical 
analysis. Graphics were made using GraphPad Prism ver-
sion 5 (GraphPad Inc., La Jolla, CA, USA).
Results
Genetic typing of clinical S. aureus isolates 
from osteomyelitis patients
Ten patients who were diagnosed with chronic osteomyeli-
tis caused by S. aureus, confirmed by deep bone culture, 
were included in this study. S. aureus isolates could be 
retrieved from bone cultures of 9 patients, and these were 
genotyped using spa typing and PFGE analysis. Eight out 
of 9 isolates contained different spa types, and PFGE anal-
ysis revealed an overall lack of relatedness between isolates 
(Fig. 1).
In addition to genetic typing, the presence of genes 
encoding 50 virulence factors of S. aureus was examined in 
the 9 clinical isolates plus the extensively studied reference 
strain NCTC 8325 using PCR (Table 1, Table S1 in Online 
Resource 2). Notably, the genes eta and etb, lukS and lukF, 
ssl9, Tst and the genes encoding 13 enterotoxins were only 
detected in a minority of the 10 isolates. The other 31 genes 
were present in at least half or more of all isolates.
Biofilm formation by clinical S. aureus isolates 
on polystyrene and human bone
Next, the ability of the 9 clinical isolates and the reference 
strain NCTC 8325 to form biofilms on polystyrene (PS) 
and freshly isolated human bone were examined. Using 
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crystal violet staining, we confirmed that all isolates were 
able to stably form biofilms on PS, although the amount of 
biofilm mass varied (Fig. 2a). Furthermore, using scanning 
electron microscopy, layers of tightly adherent bacteria 
resembling biofilms on human bone after 24-h incubation 
were visualized for one clinical isolate (Fig. 3a–c). These 
results indicate the development of mature biofilms on both 
surfaces.
Fig. 1  Genotypes of 9 clinical isolates from bone cultures. Pulsed-field gel electrophoresis data and spa types are shown. An isolate of the tenth 
patient described in this study could not be retrieved
Table 1  Presence of genes, mRNA, and protein during biofilm formation by 10 S. aureus isolates
a Only proteins are shown that were found in at least half of 9 clinical isolates and strain NCTC8325 with both transcriptomic analysis and CLA 
at minimally one time point on minimally one surface. From top to bottom, protein groups are shown that were detected in a majority of isolates 
on both PS and bone, mostly on PS, or mostly on human bone, respectively
b Number of isolates in which, respectively, the gene, mRNA, or protein was detected are shown. – indicates that the gene, mRNA, or protein 
was not detected in any isolate
Proteina Gene Functional class Strains with 
gene presentb
Biofilms on 
polystyrene
Biofilms on polystyrene Biofilms on human 
bone
mRNA presentb Significant reduction in 
specific IgGb
Significant reduction 
in specific IgGb
8 h 24 h 8 h 24 h 48 h 8 h 24 h 48 h
Alpha toxin hla Toxin 10 10 10 5 7 9 6 6 8
CHIPS chps Immune modulator 7 4 4 3 5 7 6 5 6
ClfA clfA Surface protein 10 4 4 3 6 10 7 9 10
ClfB clfB Surface protein 10 10 10 2 7 9 5 8 8
FlipR Flr Immune modulator 9 7 5 0 4 5 3 5 5
FnbA fnbA Surface protein 10 10 10 – 2 5 1 5 6
Glucosaminidase Atl Housekeeping 10 10 10 10 10 10 10 10 10
IsaA isaA Housekeeping 10 10 10 10 10 10 10 10 10
IsdA isdA Surface protein 9 9 9 9 9 9 4 8 9
Nuc nuc Housekeeping/toxin 8 5 1 7 7 8 7 8 8
SACOL0688 MntC Housekeeping 10 10 10 9 10 10 10 10 10
SCIN scn Immune modulator 10 9 8 9 9 9 9 9 9
IsdH isdH Surface protein 10 10 10 3 3 6 2 2 1
Lipase lip Housekeeping/toxin 10 10 10 1 6 8 1 2 1
SasG sasG Surface protein 7 6 6 1 1 1 7 4 2
SdrD sdrD Surface protein 7 5 5 1 1 3 2 6 6
SdrE sdrE Surface protein 7 7 6 1 1 3 5 5 5
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Characterization of IgG antibody response against S. 
aureus proteins in osteomyelitis patients
Total IgG levels directed against 50 proteins of S. aureus 
were prospectively measured during variable intervals 
within the study period (median of 26 days, interquartile 
range 9.5–85.5 days) in serum samples of the 10 patients 
(median of 4 samples per patient, interquartile range 2–5). 
Measurements for efb, EsxB, PrsA, and SA0486 were 
excluded from further analysis due to low signal intensi-
ties with coefficients of variation larger than 25 % between 
duplicate experiments.
In line with previous data [24, 26, 28], the height of all 
protein-specific IgG levels was heterogeneous between 
patients (Table 2, Table S2 in Online Resource 2), without 
any clear pattern in the course over time (Fig. S1 in Online 
Resource 3). IgG levels remained detectable up to 250 days 
within the study period. Comparison of IgG levels between 
the osteomyelitis patients, 10 patients suffering from a S. 
aureus bacteremia and 20 age-matched non-infected con-
trols, revealed that mean IgG levels differed significantly 
for 15 out of 46 proteins between groups (ANOVA p < 0.05, 
Table 2). Mean IgG levels against 10 proteins [Staphylococ-
cus aureus formyl peptide receptor-like 1 inhibitor (FLIPr), 
Fig. 2  Detection of S. aureus 
proteins during biofilm forma-
tion on PS. Biofilm mass 
formed on PS by 9 clinical 
isolates and reference strain 
NCTC 8325 (a). The levels 
of remaining non-bound IgG 
directed against specific pro-
teins in PHG after incubation 
with the biofilms [expressed 
as mean fluorescence intensity 
(MFI)], indirectly and inversely 
reflecting protein presence, are 
shown for glucosaminidase 
(b), alpha toxin (c), the non-S. 
aureus control protein PpmA 
(d). Please note the difference 
in range of MFI on the y-axis 
between Fig b–d. Dashed 
horizontal lines indicate the 
average MFI of sterile controls. 
Symbols and error bars indicate 
mean and SD of two separate 
experiments
Fig. 3  Biofilm formation of S. aureus on human bone. Cryo-scan-
ning electron microscopy of one S. aureus isolate after 24 h of bio-
film formation on human bone. Please note the different magnifica-
tions indicated by the scale bars, respectively, being 150 μm (a), 
40 μm (b), and 10 μm (c)
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glucosaminidase, gamma-hemolysin B, iron-respon-
sive surface determinant A (IsdA), leukocidins D and F, 
SACOL0699, staphylococcal complement inhibitor (SCIN), 
and Staphylococcal superantigen-like proteins 3 and 5 (SSL 
3 and 5)] were significantly higher in both osteomyelitis and 
bacteremia patients compared to controls, IgG levels against 
4 proteins (alpha toxin, exfoliative toxin A (ETA), serine–
aspartate repeat-containing protein E (SdrE), and entero-
toxin M) were significantly higher only in osteomyelitis 
patients, and IgG levels against 1 protein (IsdH) were only 
higher in bacteremia patients (Table 2). None of the mean 
protein-specific IgG levels differed significantly between 
osteomyelitis and bacteremia patients. Notably, IgG levels 
against all proteins were readily detectable in the control 
group, and IgG levels against the remaining proteins that 
are not mentioned above did not differ significantly between 
patients and controls (Table S2, Fig. S2).
Detection of proteins of S. aureus isolates during biofilm 
formation on PS
We used a competitive Luminex-based assay (CLA) 
[39, 40] to establish the presence of the same 50 proteins 
during biofilm formation by 9 of the infecting isolates 
described above. In line with previous results [39], biofilm 
mass-dependent absorption of specific IgG for several S 
aureus proteins such as glucosaminidase (Fig. 2b) was 
detected, while no such reduction was seen for IgG specific 
against non-S. aureus control proteins such as the putative 
protease maturation protein A (PpmA) of Streptococcus 
pneumoniae (Fig. 2d). Similar to the differences in biofilm 
mass (Fig. 2a), the reduction in IgG levels against most 
proteins, such as alpha toxin, was heterogeneous between 
isolates (Fig. 2c). The average amount of formed biofilm 
mass and the average percentage reduction in IgG levels 
correlated significantly for all proteins (e.g., alpha toxin: 
rs −0.77, p < 0.0001). Based on the percentage decrease 
in IgG levels against the non-S. aureus control proteins 
and against all S. aureus proteins of which the gene was 
not found in an isolate, cutoff values for protein detection 
of at least 35 % decrease in specific IgG at 24-h and 42 % 
at 48-h biofilm formation were calculated. CLA meas-
urements for four proteins (ESX-1-associated factor B 
(EsxB), extracellular fibrinogen-binding protein (efb), fol-
dase-protein PrsA, and the putative protein SA0486) were 
excluded from further analysis due to low MFIs with stand-
ard deviations larger than 25 % between repeated CLA 
measurements.
For the 31 genes that were found in at least half of the 
10 isolates, 14 proteins were detected in the majority of 
Table 2  Proteins of S. aureus associated with significantly increased IgG levels in patients
a Only proteins are shown that were associated with significantly increased IgG levels in at least one patient group. From top to bottom, protein 
groups are shown that were associated with significantly increased IgG levels in both bacteraemia and osteomyelitis patients, only in osteomyeli-
tis patients, and only in bacteraemia patients compared to controls, respectively
b Only the peak IgG levels of patients were included for comparison
c P value of ANOVA test comparing all three patient groups. P values <0.05 were considered as significant
d Groups were additionally compared using least significant difference (LSD) post hoc tests. The smallest p values, related to the significantly 
differing groups, are shown
Proteina Gene Function class Mean IgG level 
control patients 
(±SD; N = 20)
Mean IgG level 
bacteremia patients 
(±SD; N = 10)b
Mean IgG level 
osteomyelitis patients 
(±SD; N = 10)b
P value 
ANOVAc
P value Post 
hoc analysisd
FlipR flr Immune modulator 1864 (±1569) 4490 (±3485) 3656 (±2143) 0.007 0.019
Glucosaminidase Atl Housekeeping 5273 (±2827) 86,780 (±3612) 8377 (±3882) 0.005 0.019
HlgB hlgB Toxin 6328 (±4290) 10,838 (±2924) 10,917 (±3627) 0.002 0.007
IsdA isdA Surface protein 3722 (±4532) 6534 (±3993) 5016 (±2756) 0.006 0.023
LukD lukD Toxin 6311 (±3988) 9512 (±3514) 9369 (±3581) 0.024 0.044
LukF lukF Toxin 1105 (±880) 1851 (±772) 2025 (±917) 0.001 0.005
SACOL0688 MntC Housekeeping 839 (±650) 3849 (±4290) 2572 (±2432) 0.001 0.005
SCIN scn Immune modulator 3665 (±3322) 7939 (±3805) 7545 (±3782) <0.000 0.002
SSL3 ssl3 Immune modulator 4679 (±3068) 8186 (±4746) 6955 (±3673) 0.011 0.042
SSL5 ssl5 Immune modulator 1929 (±1307) 4675 (±3315) 3932 (±2827) 0.001 0.014
Alpha toxin hla Toxin 8895 (±4419) 11,610,9 (±5117) 14,884,3 (±3749) 0.037 0.011
ETA eta Toxin 893 (±1425) 1238 (±1946) 2874 (±4178) 0.026 0.007
SdrE sdrE Surface protein 293 (±298) 399 (±385) 651 (±441) 0.026 0.007
SEM sem Toxin 526 (±542) 1155 (±1595) 1322 (±966) 0.028 0.011
IsdH isdH Surface protein 825 (±867) 2579 (±3130) 2732 (±4407) 0.034 0.011
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gene-positive isolates at minimally one time point (8, 24, 
and/or 48 h) during biofilm formation on PS (Table 1): the 
surface proteins clumping factor A and B (ClfA and B), 
fibronectin-binding protein A (FnbpA), IsdA and H, the 
housekeeping proteins glucosaminidase, immunodominant 
antigen A (IsaA), lipase, nuclease, and the putative ABC 
transporter SACOL0688, the immune modulators FlipR, 
SCIN, and chemotaxis inhibitory protein of S. aureus 
(CHIPS), and alpha toxin.
For the genes that were found in a minority of isolates, 
the proteins exfoliative toxin A (ETA) and the staphylococ-
cal enterotoxins A, B, D, Q, and R were detected in one to 
maximally three gene-positive isolates during biofilm for-
mation on PS (Table S1 in Online Resource 2). Using the 
above-mentioned cutoff values, no proteins were detected 
when the corresponding gene was absent in an isolate.
The lack of detection of several secreted proteins, 
despite the presence of corresponding genes in isolates 
(Table S1 in Online Resource 2), prompted us to repeat 
CLA experiments using the medium covering biofilms 
instead of biofilms self. Results obtained with medium 
showed similar reduction in IgG levels against all pro-
teins, including secreted proteins such as alpha toxin, com-
pared to results obtained with biofilms (Fig. S3 in Online 
Resource 3). This suggests that the lack of protein detection 
is not due to false-negative signals. CLA data were further 
confirmed by the detection of specific mRNA at 8 and/or 
24 h of biofilm formation for all detected proteins (Table 1; 
Table S1 in Online Resource 2).
Detection of proteins of S. aureus isolates during biofilm 
formation on human bone
In an attempt to examine the expression of S. aureus viru-
lence factors in an environment that more closely resembles 
the in vivo conditions during osteomyelitis, we repeated 
the above-mentioned experiments with biofilms grown on 
human bone. Generally, the same patterns of reduction in 
specific IgG levels were observed as for biofilms on PS, 
including for glucosaminidase, alpha toxin, and the PpmA 
control protein (Fig. 4a–c). Compared to biofilm forma-
tion on PS, similar percentages of non-specific reduction in 
IgG levels were found, prompting us to use the same cutoff 
values.
For the 31 genes that were found in half or more of 
the 10 isolates, 15 proteins were detected in the majority 
of gene-positive isolates at minimally one time point (8, 
24, and/or 48 h) during biofilm formation on human bone 
(Table 1). These were largely the same proteins that were 
also detected during biofilm formation on PS, with the 
exception of IsdH and lipase, which were detected in only 
a minority of isolates at all time points. On the other hand, 
S. aureus surface protein G (SasG) and SD-repeat-contain-
ing proteins D and E (SdrD and E) were detected in most 
isolates during biofilm formation on bone but not on PS at 
several time points (Table 1).
Notably, for the genes that were found in a minority of 
isolates, all Staphylococcal enterotoxins were detected 
in 1–4 gene-positive isolates during biofilm formation on 
bone, which were more isolates compared to the results 
obtained with biofilms on PS (Table S1 in Online Resource 
2).
Comparison of in vivo antibody responses with in vitro 
protein detection
For the 31 genes that were found in at least half of the 10 
isolates, 8 S. aureus proteins were associated with signifi-
cantly increased IgG levels in patients and detectable in the 
majority of the gene-positive isolates during biofilm forma-
tion on PS and/or bone: alpha toxin, FlipR, glucosamini-
dase, IsdA and H, SACOL0688, SCIN, and SdrE. Among 
the less common genes, enterotoxin M was associated with 
significantly increased IgG levels in patients, and it was 
Fig. 4  Detection of S. aureus proteins during biofilm formation on 
human bone. The levels of remaining non-bound IgG directed against 
specific proteins after incubation of PHG with biofilms of 9 clinical 
isolates and strain NCTC 8325 on bone (expressed in MFI) are shown 
for glucosaminidase (a), alpha toxin (b), and the non-S. aureus con-
trol protein PpmA (c). Dashed horizontal lines indicate the average 
MFI of sterile controls. Symbols and error bars indicate mean and SD 
of two separate experiments
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detectable in multiple isolates specifically during biofilm 
formation on bone.
In contrast to the above-mentioned results, the toxins 
hemolysin gamma-B and leucocidin D and the immune 
modulators SSL3 and 5 were associated with significantly 
increased IgG levels in patients but detected in only a 
minority of gene-positive isolates during biofilm formation 
in vitro. Vice versa, the surface proteins ClfA and B and 
the housekeeping proteins IsaA, lipase, and nuclease were 
detected in a majority of strains during biofilm formation 
in vitro but were not associated with significantly increased 
IgG levels in patients. The latter was also true for the less 
common enterotoxins B and Q, for which genes were pre-
sent in 3 and 2 isolates, respectively.
Discussion
In this study, we characterized the IgG response against 
50 functionally diverse proteins of S. aureus in patients 
with chronic osteomyelitis. IgG levels against 14 diverse 
virulence factors, such as alpha toxin, the surface protein 
IsdA, and the housekeeping protein glucosaminidase, were 
significantly increased in osteomyelitis patients compared 
to healthy controls. Interestingly, a comparison with peak 
IgG levels of patients suffering from a S. aureus bactere-
mia revealed little difference, suggesting that immunologi-
cal exposure to specific virulence factors is similar during 
both infections. Indeed, bacteria residing within a biofilm 
can dislodge and potentially cause a bacteremia [42]. This 
implicates that it might be difficult to find serological mark-
ers that can specifically discriminate between a S. aureus 
osteomyelitis and other sorts of infection. Moreover, in the 
context of identifying potential targets for example vacci-
nation, this implicates that results of immunological in vivo 
studies should be interpreted cautiously when searching for 
targets that are specifically involved in biofilm formation.
To gain further insight into the involvement of the 
50 proteins mentioned above in biofilm formation, we 
screened for the presence of these proteins during biofilm 
formation of 9 clinical isolates and reference strain NCTC-
8325 on polystyrene (PS) and freshly isolated human bone, 
using a novel competitive Luminex-based assay (CLA). 
In general, we observed a clear variation in the reduction 
in protein-specific IgG levels between isolates, which can 
largely be explained by differences in the amount of bio-
film mass formed by each isolate. This variability in bio-
film mass is in line with previous results, which might be 
related to the different genetic backgrounds of the isolates 
[43].
For the 31 proteins of which genes were present in at 
least half of the 9 clinical isolates and NCTC 8325, 12 
proteins were detected in at least half of all isolates at 
minimally one time point (8, 24, and/or 48 h) during bio-
film formation on both PS and bone. Several of these pro-
teins, especially surface proteins such as ClfB and FnbpA, 
already have a known role in biofilm formation [44–46]. 
In addition, several detected proteins, including IsaA, 
SACOL0688, and glucosaminidase, have been successfully 
evaluated as vaccine targets in animal infection models, 
some specifically in an osteomyelitis model [16, 47]. Our 
results further indicate the potential use of these proteins 
as vaccine targets by demonstrating their actual production 
during biofilm formation by genetically diverse clinical iso-
lates ex vivo and, based on antibody responses, also during 
osteomyelitis in human patients in vivo.
Although the CLA results between biofilm formation 
on PS and bone generally agreed well, detection of a few 
proteins differed. Lipase and IsdH were mostly detected 
on PS while the biofilm-associated surface proteins SasG, 
SdrD, and SdrE were mostly detected on bone. In addi-
tion, also the genetically less common enterotoxins were 
detected relatively more often on bone. The presence of 
SdrE and D specifically during biofilm formation on bone 
might be explained by bacterial attachment to the calcium-
rich extracellular matrix, as these proteins are structurally 
dependable on calcium [48]. Although we cannot currently 
explain the other observed differences, we have demon-
strated before using CLA that different circumstances can 
impact protein detection in vitro and ex vivo [39, 40]. In 
this context, production of some of the above-mentioned 
proteins, including diverse enterotoxins, is regulated by the 
accessory gene regulatory (Agr) quorum-sensing system 
[49, 50]. Possibly, this system is activated differently upon 
interaction of S. aureus with either PS or bone. Lastly, next 
to culture circumstances also the timing of measurement 
can be influential, as demonstrated by the detection of SasG 
mostly during early biofilm formation (8 h), which is in 
line with its established role during the early accumulation 
phase [51]. Together, these findings implicate that results 
from in vitro models should be interpreted cautiously, and 
both timing and circumstances during the measurement 
should be taken into account.
Combination of in vitro and in vivo results suggests 
that 8 proteins, of which most are already discussed above, 
are both immunogenic in patients and are detectable in 
the majority of clinical isolates during biofilm formation. 
At the same time, some toxins and immune modulators 
were associated with significantly increased IgG levels in 
patients but not detected during biofilm formation in vitro. 
Possibly, our in vitro biofilm model might not adequately 
reflect the in vivo situation in patients, or the measured 
IgG levels might be mounted against proteins produced by 
planktonic growing bacteria within the patient. Moreover, 
IgG levels against the leukocidins might be false-positive 
due to the presence of cross-reactive antibodies, which has 
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been established before in our assay [29]. In contrast to the 
above-mentioned proteins, other proteins such as the ubiq-
uitously present clumping factors and IsaA were detected 
in vitro but not associated with significantly increased 
IgG levels in patients. This might well be explained by the 
high IgG levels that we found in both healthy controls and 
in patients, thereby eliminating any statistically signifi-
cant difference between groups. Indeed, antibody titers to 
diverse S. aureus proteins appear to be ubiquitously present 
in the general population [24, 28], and this appears to be 
mostly independent of nasal carrier ship for S. aureus [41] 
cautiously.
A limitation of the current Luminex assay is that its sen-
sitivity is potentially influenced by amino acid sequence 
diversity, which is described for multiple proteins described 
in this study [52–55]. However, in general sequence diver-
sity has been described within certain limits, and these dif-
ferences do not significantly impact our assay sensitivity, 
based on cross-reactivity within our assay as shown earlier 
for the leukocidin components and hemolysin gamma-B 
[29] and also the more variable, different isotype forms of 
the FnBPA A domain [52] (data in submission). In addi-
tion, we only compare average IgG levels for each protein 
separately, further levelling out potential variation in assay 
sensitivity due to protein diversity. Taken together, we are 
confident that the current assay allows us to screen for the 
presence of specific antibodies and proteins [29, 40].
The 50 proteins included in the current assay were cho-
sen based on their established roles in S. aureus pathogen-
esis and the corresponding host immune response. How-
ever, there are many more, e.g. cytosol-based proteins of 
S. aureus that remain less-characterized in this context, yet 
could also be potentially interesting therapeutic targets. We 
believe that these proteins will be an interesting addition to 
future immunoproteomic studies, although this is not the 
focus of the current study.
We conclude that functionally diverse virulence fac-
tors of S. aureus are present during biofilm formation by 
genetically diverse isolates on PS and human bone in vitro, 
and that some of these proteins are immunogenic in vivo. 
These observations merit more mechanistic studies to elu-
cidate the function of specific proteins and the regulation of 
their expression during S. aureus biofilm formation. How-
ever, the present data further suggest that multiple proteins, 
such as the ubiquitously present and immunogenic IsdA or 
SA0688, could be potential targets for novel agents such as 
a multivalent vaccine to prevent or treat biofilm-associated 
infections in patients. Combined studies using both in vitro 
models and immunological assays in patients in vivo can 
help in identifying novel therapeutic targets.
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